Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03560583|
Recruitment Status : Not yet recruiting
First Posted : June 18, 2018
Last Update Posted : July 4, 2019
Poor ovarian response population of ART are considered the biggest challenge for providers. Hitherto, no one protocol has been proven to be effect in this subgroup of IVF patients.
Metoclopramide belongs to the antiemetic group, used for motion sickness and during early gestation for hyperemesis gravidarum.
The mechanism of action is antagonisim to dopamine receptors. We hypothesize than by blocking dopamine receptors and decreasing the dopaminergic tone there is a possibility to increase the sensitivity of ovarian response to gonadotropins during controlled ovarian stimulation and result in increased oocyte retrival.
|Condition or disease||Intervention/treatment||Phase|
|Poor Responders in IVF||Drug: Metoclopramide Drug: Placebo Oral Tablet||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Efficacy of Metoclopramide in Poor Ovarian Response IVF Patients: a Randomised, Double-blind, Placebo-controlled Trial|
|Estimated Study Start Date :||July 2019|
|Estimated Primary Completion Date :||July 2022|
|Estimated Study Completion Date :||July 2022|
|Experimental: Metoclopramide 10 mg BID||
Metoclopramide 10 mg BID
|Placebo Comparator: Placebo 10 mg BID||
Drug: Placebo Oral Tablet
Placebo 10 mg BID
- Number of oocytes [ Time Frame: Approximately 5 weeks from first dose of study drug ]Number of oocytes
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03560583
|Contact: Leon Grin, MDfirstname.lastname@example.org|
|Principal Investigator:||Leon Grin, MD||Barzilai Medical Center|